'김갑성' 기자의 전체기사
-
NovaBridge Subsidiary Visara Assigns Its Exclusive License…
[ 메디채널 김갑성 기자 ] NovaBridge subsidiary Visara assigned its exclusive license to Everest Medicines to accelerate the development of potential best-in-class therapy for wet AMD, VIS-101, leveraging Everest Medicines' strong clinical and commercialization expertise in Greater China and other Asian markets NovaBridge also named Mr. Ian Woo, President and Chief Financial Officer of Everest Medicines, to its Board of Directors, bringing substantial expertise in international biopharma finance, operations and management VIS-101 is a novel bifunctional biologic targeting VEGF-A/ANG2, with potenti
- 김갑성 기자
- 2025-10-30 16:15
-
U.S. FDA grants interchangeability designation to Celltrion's d…
The U.S. FDA approved STOBOCLO® (denosumab-bmwo) and OSENVELT® (denosumab-bmwo) as interchangeable with the reference products PROLIA® (denosumab) and XGEVA® (denosumab), respectively, for all approved indications, effective as of October 29, 2025 The interchangeability (IC) designations of STOBOCLO and OSENVELT were granted based not only on the comparative clinical data – including pharmacokinetics, efficacy, safety and an immunogenicity study in postmenopausal women with osteoporosis[1] - but also on analytical data demonstrating similarity of STOBOCLO and OSENV
- 김갑성 기자
- 2025-10-30 15:28
-
United Imaging Healthcare Q3 2025 Results: In The First Three…
SHANGHAI, Oct. 30, 2025 -- United Imaging Healthcare (SSE: 688271), a global leader in advanced medical imaging and radiotherapy equipment, has released its financial results for the first three quarters of 2025, showcasing robust financial performance. During this period, the company's revenue and net profit attributable to ordinary shareholders after deducting non-recurring profit, reached CNY 8.86 billion and 1.05 billion, representing a year-over-year increase of 27.39% and 126.94%, respectively. In Q3 2025, the company achieved revenue of CNY 2.84 billion, up 75.41% year on year,
- 김갑성 기자
- 2025-10-30 13:58
-
Everest Medicines Acquires Exclusive Greater China and Oth…
[ 메디채널 김갑성 기자 ] Everest Medicines acquired an exclusive license to develop, manufacture, and commercialize VIS-101 in Greater China, Singapore, South Korea, and certain Southeast Asian countries. Under the assigned exclusive license, Everest Medicines will make an upfront payment of US$7 million (equivalent to approximately RMB49.7 million) and reimburse up to RMB24.0 million for prior expenses; and pay up to US$89.0 million (equivalent to approximately RMB632.0 million) in potential milestones; plus tied royalties on net sales. VIS-101 is a novel bifunctional biologic targeting VEGF-A a
- 김갑성 기자
- 2025-10-30 11:05
-
LOTTE BIOLOGICS and SK pharmteco Sign Strategic Partnershi…
Two global CDMO leaders have joined forces to strengthen their presence in the rapidly growing antibody-drug conjugate (ADC) market. The collaboration will deliver integrated, one-stop CDMO services spanning antibody drug substance, linker–payload production, and bioconjugation, supported by joint marketing based on deep ADC expertise. SEOUL, South Korea, Oct. 30, 2025 -- LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent (LOI) for a strategic collaboration to strengthen their competitiveness in the g
- 김갑성 기자
- 2025-10-30 09:15
-
ArkBio Initiates Phase II Clinical Trial of AK0610, a Preventive Mon…
SHANGHAI, Oct. 30, 2025 -- Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a fully human monoclonal antibody designed to prevent respiratory syncytial virus (RSV) infection. Building on ArkBio's previous experience and knowledge in development of RSV therapeutics, this milestone marks a major step forward in RSV prevention and enriches the company's innovative anti-RSV drug portfolio. The multicenter, randomized, double-blind, placebo-controlled, dose-escalation phase II study wil
- 김갑성 기자
- 2025-10-30 09:00
-
Jenscare released its multi-product portfolio's, including L…
BEIJING, Oct. 30, 2025 -- Jenscare Scientific Co., Ltd. ("Jenscare" or the "Company") (HKEX: 9877), an innovative medical device company, recently released 6-month follow-up results of TRINITY Trial of LuX-Valve Plus, a promising self-developed TTVR system, and 1-year outcomes and challenging cases of JensClip and Ken-Valve, a proprietary TMVr system and TAVR (AR) system respectively, representing the Company's diversified and high-potential multi-product portfolio, at TCT 2025 in the U.S.. 6-Month Follow-up Results of LuX-Valve Plus TRINITY Study-Released by Prof.
- 김갑성 기자
- 2025-10-30 09:00
-
Ascletis Selects a Best-in-Class Once-Monthly Subcutaneo…
-In head-to-head non-human primate (NHP) studies, average observed half-life of ASC36 was approximately 15 days, 3-fold longer than petrelintide, which supports once-monthly subcutaneous (SQ) dosing in humans. -ASC36 demonstrated approximately 91% greater relative body weight reduction compared to petrelintide in a head-to-head diet-induced obese (DIO) rat study. -ASC36 has excellent chemical and physical stability with no fibrillation around neutral pH, allowing for co-formulation with other peptides including ASC35, a GLP-1R/GIPR dual agonist. -Submission of an Investi
- 김갑성 기자
- 2025-10-30 08:10
-
색상 측정 분야를 혁신할 헌터랩 Agera L2, 11월 공식 출시
레스턴, 버지니아주, 2025년 10월 30일 -- 색상 측정 분야가 일대 혁신을 앞두고 있다. 헌터랩(HunterLab)이 11월 혁신적인 차세대 분광광도계(spectrophotometric) 제품 Agera L2를 공개한다. Agera L2는 전 세계의 색상 측정과 인식 방식을 새롭게 정의할 예정이다. Agera L2는 계측적 색상 측정과 인간의 눈이 색상을 인지하는 방식을 일치시키려는 헌터랩의 지속적인 노력이 이뤄낸 중대한 진전이다. 정밀성, 속도, 사용성을 종합적으로 고려해 설계된 이 제품은 계산된 색상 값과 시각적 평가 사이의 격차를 해소하는 기술을 도입했다. 핵심 기술은 자연광을 완벽하게 재현한 광원인 True D65 일광 조명이다. 이러한 기술적 발전 덕분에 사용자는 실제 일광 조건에서 보는 그대로 색상을 측정할 수 있다. 실험실에서 측정하는 높은 정밀성과 실제 환경에서 인간의 눈으로 인지하는 색상이 이제 하나의 기기 안에서 일치하게 된 것이다. Agera L2는 UltraDark 성능(극도로 낮은 밝기 측정 성능)과 결합되어 가장 어둡고 빛을 많이 흡수하는 소재에서도 뛰어난 정확도를 보여준다. 또한 이
- 김갑성 기자
- 2025-10-30 08:00
-
Jungbunzlauer Tricalcium Citrate Excipient Demonstrates Ou…
- New research confirms Jungbunzlauer's TCC TB supports efficient, high-quality tablet manufacturing across challenging pharmaceutical and nutraceutical applications - BASEL, Switzerland, Oct. 29, 2025 -- Jungbunzlauer, a global leader in high-quality, sustainable ingredients, and Professor Karl Wagner from the University of Bonn, announce the results of new research confirming Jungbunzlauer's tricalcium citrate (TCC TB) sets a new standard for direct compression in pharmaceutical and nutraceutical tablet manufacturing. "This collaboration with Professor Wa
- 김갑성 기자
- 2025-10-29 23:21
- 1포리프 굿마팻 (누바디 굿바이 마이팻) 다이어트 건강기능식품 출시
- 22021년 식품분석전문가 1급/2급 검정자격시험 안내
- 3투썸플레이스, 초콜릿 애프리콧 무스 출시
- 4만성질환자들의 유료독감백신접종에 정책적인 배려가 필요하다
- 5아임웹, CRM 기능 출시… 고객 행동 데이터 기반 마케팅 지원
- 6하만카돈, AURA STUDIO 4 블루투스 스피커 출시
- 7대구오페라하우스 - 20주년 기념 골든 보이스 시리즈Ⅲ, 테너 콘서트
- 82021년 대학생기자단 모집
- 9대한약물영양의학회 2020년 추계학술대회
- 10대한영양제처방학회 춘계학술대회 성황리에 마쳐
2025-12-11_THU
- ADI Foundation、ADI ChainのメインネットとADIユーティリティトークンのローンチを発表 02:48
- ADI 재단, ADI 체인 메인넷 및 ADI 유틸리티 토큰 출시 02:31
- ADFW's Fintech Abu Dhabi Points to a New Era of Finance Fuelled by Innovation and Disruption 02:02
- カタール博物館のTasweer 、「文化の年（Years of Culture）」の一環として「一つの空の下（Under One Sky）」世界写真公募を発表 00:54
- 카타르 박물관 타스위르, '같은 하늘 아래' 국제 사진 공모전 개최 00:29
2025-12-10_WED
발행인 : 최희정 | 편집인 : 김갑성 |
등록번호: 서울특별시 아53302 | 등록일 2020-09-25 | 전화번호 02-565-7119 |
주소 : 서울특별시 강남구 영동대로 602, 6층 E115 (삼성동)
Copyright @메디채널 Corp. All rights reserved.
UPDATE: 2025년 12월 11일 04시 20분